| Exclusion Criteria: | 1) have uncontrolled life-threatening infection (or active infectious process requiring IV systemic medical therapy within one week prior to study enrollment).
2) have previously received HSCT.
3) are planning a tandem transplant.
4) are female with a positive pregnancy test, are pregnant, or lactating and breast-feeding, or wish to become pregnant during the course of the study. Patients unwilling to use a barrier method of contraception or who in the investigator's judgment would not be compliant in using an effective method of contraception will be excluded.
5) are receiving estrogen or testosterone replacement therapy, oral contraceptives (patients may enroll is oral contraceptives are ceased prior to study entry), or have been administered Depo Provera within 3 months of entering the study.
6) have had prior mediastinal or sternal radiation.
7) have received any investigational drug other than antibiotics within 3 weeks prior to study drug administration or are scheduled to receive an investigational drug during the course of this study. Exceptions must be approved by the study chairman in writing and recorded in study records.
8) have unstable cardiac arrhythmias, uncontrolled congestive heart failure, history of MI or ischemia, stroke, or embolic events within 6 months before study start.
9) have medical or psychiatric conditions that, in the opinion of the investigator, would compromise the patient's ability to participate in the study.
10) are currently receiving corticosteroid therapy (in doses greater than hydrocortisone 50 mg). Patients are not eligible if they are receiving steroids at the time of study entry. After the patients are on study, they may receive steroid treatment if necessary, with the approval of the study chairman.
11) are or will be receiving palifermin (KGF).
12) have a Shellfish allergy.
13) have had a suspected or diagnosed schistosomiasis infection.
14) are currently or have previously taken a GNRH analog. |